[HTML][HTML] Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability
AJ Garber - Diabetes care, 2011 - ncbi.nlm.nih.gov
Targeting the incretin system has become an important therapeutic approach for treating
type 2 diabetes. Two drug classes have been developed: glucagon-like peptide (GLP)-1 …
type 2 diabetes. Two drug classes have been developed: glucagon-like peptide (GLP)-1 …
[PDF][PDF] Long-Acting Glucagon-Like Peptide 1 Receptor Agonists
AJ GARBER - DIABETES CARE, 2011 - Citeseer
Targeting the incretin system has become an important therapeutic approach for treating
type 2 diabetes. Two drug classes have been developed: glucagon-like peptide (GLP)-1 …
type 2 diabetes. Two drug classes have been developed: glucagon-like peptide (GLP)-1 …
[PDF][PDF] Long-Acting Glucagon-Like Peptide 1 Receptor Agonists
AJ GARBER - DIABETES CARE, 2011 - scienceopen.com
Targeting the incretin system has become an important therapeutic approach for treating
type 2 diabetes. Two drug classes have been developed: glucagon-like peptide (GLP)-1 …
type 2 diabetes. Two drug classes have been developed: glucagon-like peptide (GLP)-1 …
Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability.
AJ Garber - Diabetes Care, 2011 - europepmc.org
Targeting the incretin system has become an important therapeutic approach for treating
type 2 diabetes. Two drug classes have been developed: glucagon-like peptide (GLP)-1 …
type 2 diabetes. Two drug classes have been developed: glucagon-like peptide (GLP)-1 …
[引用][C] Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability
AJ Garber - Diabetes care, 2011 - pubmed.ncbi.nlm.nih.gov
[引用][C] Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and tolerability
AJ GARBER - Diabetes care. Supplement, 2011 - pascal-francis.inist.fr
Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and
tolerability CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases …
tolerability CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases …
[引用][C] Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and tolerability
AJ Garber - Diabetes Care, 2011 - Am Diabetes Assoc
Targeting the incretin system has become an important therapeutic approach for treating
type 2 diabetes. Two drug classes have been developed: glucagon-like peptide (GLP)-1 …
type 2 diabetes. Two drug classes have been developed: glucagon-like peptide (GLP)-1 …
Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and tolerability
AJ Garber - Diabetes Care, 2011 - search.proquest.com
Furthermore, although nausea is a common side effect with longacting GLP-1 receptor
agonists, it tends to be transient and, overall, long-acting GLP-1 receptor agonists are …
agonists, it tends to be transient and, overall, long-acting GLP-1 receptor agonists are …
Long-Acting Glucagon-Like Peptide 1 Receptor Agonists.
AJ GARBER - Diabetes Care, 2011 - search.ebscohost.com
The article examines the efficacy and tolerability of long-acting glucagon-like peptide 1
receptor agonists. The two classes of drugs for treating type 2 diabetes are glucagon-like …
receptor agonists. The two classes of drugs for treating type 2 diabetes are glucagon-like …
Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability
AJ Garber - Diabetes Care, 2011 - go.gale.com
Targeting the incretin system has become an important therapeutic approach for treating
type 2 diabetes. Two drug classes have been developed: glucagon-like peptide (GLP)-1 …
type 2 diabetes. Two drug classes have been developed: glucagon-like peptide (GLP)-1 …